Literature DB >> 11514915

The modern age of acne therapy: a review of current treatment options.

S V Bershad1.   

Abstract

This review of current acne treatments begins with the crucial discovery in 1979 of isotretinoin treatment for nodulocystic acne. This drug s approval in 1982 revolutionized therapy, since it was the first oral acne-specific drug, and it provided prolonged remissions. In addition, it may prevent the emergence of resistant bacteria, a problem linked to the traditional use of antibiotics for acne. Patients who are not candidates for isotretinoin therapy may benefit from one of the other drugs or drug combinations reviewed, including the third-generation topical retinoids adapalene and tazarotene, retinoic acid reformulated in new vehicles, azelaic acid, and topical antibiotics. Proper selection and education of patients are essential, since serious consequences may result from poorly monitored use of antibiotics and retinoid.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11514915

Source DB:  PubMed          Journal:  Mt Sinai J Med        ISSN: 0027-2507


  4 in total

1.  The effect of isotretinoin on meibomian glands in eyes: a pilot study.

Authors:  Ugur Gurlevik; Funda Kemeriz; Erdogan Yasar
Journal:  Int Ophthalmol       Date:  2022-01-03       Impact factor: 2.029

Review 2.  Transdermal penetration of topical drugs used in the treatment of acne.

Authors:  Andrea Krautheim; Harald Gollnick
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Adapalene: a review of its use in the treatment of acne vulgaris.

Authors:  John Waugh; Stuart Noble; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Explore the Anti-Acne Mechanism of Licorice Flavonoids Based on Metabonomics and Microbiome.

Authors:  Shi-Fa Ruan; Yi Hu; Wen-Feng Wu; Qun-Qun Du; Zhu-Xian Wang; Ting-Ting Chen; Qun Shen; Li Liu; Cui-Ping Jiang; Hui Li; Yankui Yi; Chun-Yan Shen; Hong-Xia Zhu; Qiang Liu
Journal:  Front Pharmacol       Date:  2022-02-08       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.